BiotechTube

Mogamulizumab

ApprovedActive
4 views this week 0 watching⚡ Active🧪Featured in Gene & Cell Therapy Watch
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Cutaneous T-Cell Lymphoma

Conditions

Cutaneous T-Cell Lymphoma

Trial Timeline

May 29, 2023 → Nov 13, 2025

NCT ID
NCT06285370

About Mogamulizumab

Mogamulizumab is a approved stage product being developed by Kyowa Kirin for Cutaneous T-Cell Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT06285370. Target conditions include Cutaneous T-Cell Lymphoma.

What happened to similar drugs?

6 of 19 similar drugs in Cutaneous T-Cell Lymphoma were approved

Approved (6) Terminated (1) Active (12)
✅ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
✅ONTAKEisaiApproved
🔄E7777 9 mcg/kgEisaiPhase 3
✅ONTAKEisaiApproved
🔄KW-0761 + VorinostatKyowa KirinPhase 3
✅Clopidogrel + TicagrelorAstraZenecaApproved
🔄TR-701 FA + LinezolidMerckPhase 3

Hype Score Breakdown

Clinical
20
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06285370ApprovedActive
NCT04745234Phase 2Active

Competing Products

20 competing products in Cutaneous T-Cell Lymphoma

See all competitors
ProductCompanyStageHype Score
ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
43
ONTAKEisaiApproved
43
E7777 9 mcg/kgEisaiPhase 3
40
ONTAKEisaiApproved
43
Mogamulizumab + Brentuximab vedotinKyowa KirinPhase 1
36
MogamulizumabKyowa KirinPhase 2
39
KW-0761 + VorinostatKyowa KirinPhase 3
40
EnzastaurinEli LillyPhase 2
35
Clopidogrel + TicagrelorAstraZenecaApproved
43
PembrolizumabMerckPhase 2
42
Comparator: vorinostatMerckPre-clinical
26
PembrolizumabMerckPhase 2
39
TR701 FAMerckPhase 2
35
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 MonthsMerckPhase 2
35
PembrolizumabMerckPhase 2
42
Tulisokibart + PlaceboMerckPhase 2
39
Aspirin + Ipilimumab + PembrolizumabMerckPhase 2
35
Pembrolizumab + MogamulizumabMerckPhase 2
42
TR-701 FA + LinezolidMerckPhase 3
40
Pimasertib + DacarbazineMerckPhase 2
35